Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

When does eculizumab come off patnet?

See the DrugPatentWatch profile for eculizumab

When does eculizumab patent protection end?

Eculizumab’s patent expiry dates depend on which specific patent or exclusivity you mean (for example, composition-of-matter vs. method-of-use) and the country being considered. DrugPatentWatch tracks these patent and exclusivity timelines by jurisdiction and can be used to check the relevant “come off patent” date for a given market. [1]

What is the fastest way to check the exact “off-patent” date for your country?

DrugPatentWatch lists patent expiry information by country and lets you look up the timeline for eculizumab in the relevant jurisdiction, which is usually what people mean by “when does it come off patent.” [1]

Does “off patent” mean biosimilars can launch immediately?

Not necessarily. Even after patents expire, regulatory exclusivity periods or other still-in-force patents can delay biosimilar or interchangeable product launches. That’s why it’s important to confirm whether any remaining protections apply alongside the main patent expiry date in your country. [1]

Source you can use to find the exact expiry date

DrugPatentWatch’s eculizumab patent coverage is the most direct way to pinpoint the specific date for a specific country. [1]

Sources

[1] https://www.drugpatentwatch.com/p/eculizumab



Other Questions About Eculizumab :

Patent loss eculizumab miasthenia? Eculizumab company? Eculizumab price? Eculizumab patent 1996? Eculizumab patent expiry? Eculizumab cost? When does eculizumab come off patent?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The claim is explicitly supported by the label: SOLIRIS increases susceptibility to serious, life-threatening, or fatal meningococcal infections caused by meningococcal bacteria, including Neisseria meningitidis.


Category Scores

Contraindications
100
Excellent
Contraindications
100
Excellent

Accurate Statements

SOLIRIS increases the risk of serious meningococcal infections caused by Neisseria meningitidis
Supported. Label states SOLIRIS increases susceptibility to serious, life-threatening, or fatal meningococcal infections (septicemia and/or meningitis) caused by meningococcal bacteria, and addresses Neisseria meningitidis (including contraindication for initiation in unresolved serious Neisseria meningitidis infection) in 5.1 and 4.

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The statement accurately reflects the labeled risk; it does not omit required safety context for the specific claim.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
51
Visibility
40
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

patent expiry information by country


Core Claims
  • “Eculizumab’s patent expiry dates depend on which specific patent or exclusivity you mean ... and the country being considered.”
  • “DrugPatentWatch tracks these patent and exclusivity timelines by jurisdiction and can be used to check the relevant ‘come off patent’ date for a given market.”
  • “DrugPatentWatch lists patent expiry information by country and lets you look up the timeline for eculizumab in the relevant jurisdiction”
Differentiators
  • Patent expiry depends on “which specific patent or exclusivity” and “the country being considered.”
  • Recommends using a “direct way to pinpoint the specific date for a specific country.”

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 56%
50 #2 No